Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Young Nam Kim"

Article category

Keywords

Publication year

"Young Nam Kim"

Original Article

Viral hepatitis

Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection
Yoo-Kyung Cho, Young Nam Kim, Byung-Cheol Song
Clin Mol Hepatol 2014;20(4):368-375.
Published online December 24, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.4.368
Background/Aims

This study evaluated the predictors of spontaneous viral clearance (SVC), as defined by two consecutive undetectable hepatitis C virus (HCV) RNA tests performed ≥12 weeks apart, and the outcomes of acute hepatitis C (AHC) demonstrating SVC or treatment-induced viral clearance.

Methods

Thirty-two patients with AHC were followed for 12-16 weeks without administering antiviral therapy.

Results

HCV RNA was undetectable at least once in 14 of the 32 patients. SVC occurred in 12 patients (37.5%), among whom relapse occurred in 4. SVC was exhibited in 8 of the 11 patients exhibiting undetectable HCV RNA within 12 weeks. HCV RNA reappeared in three patients (including two patients with SVC) exhibiting undetectable HCV RNA after 12 weeks. SVC was more frequent in patients with low viremia than in those with high viremia (55.6% vs. 14.3%; P=0.02), and in patients with HCV genotype non-1b than in those with HCV genotype 1b (57.1% vs. 22.2%; P=0.04). SVC was more common in patients with a ≥2 log reduction of HCV RNA at 4 weeks than in those with a smaller reduction (90% vs. 9.1%, P<0.001). A sustained viral response was achieved in all patients (n=18) receiving antiviral therapy.

Conclusions

Baseline levels of HCV RNA and genotype non-1b were independent predictors for SVC. A ≥2 log reduction of HCV RNA at 4 weeks was a follow-up predictor for SVC. Undetectable HCV RNA occurring after 12 weeks was not sustained. All patients receiving antiviral therapy achieved a sustained viral response. Antiviral therapy should be initiated in patients with detectable HCV RNA at 12 weeks after the diagnosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Elucidating the distinct contributions of miR-122 in the HCV life cycle reveals insights into virion assembly
    Marylin Rheault, Sophie E Cousineau, Danielle R Fox, Quinn H Abram, Selena M Sagan
    Nucleic Acids Research.2023; 51(5): 2447.     CrossRef
  • Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a
    Hang Zhang, Ahmed A. Quadeer, Matthew R. McKay
    iScience.2022; 25(1): 103569.     CrossRef
  • Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children
    Magdalena Pluta, Maria Pokorska-Śpiewak, Małgorzata Aniszewska, Barbara Kowalik-Mikołajewska, Magdalena Marczyńska
    Klinische Pädiatrie.2021; 233(05): 211.     CrossRef
  • Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study
    Alicja E. Grzegorzewska, Adrianna Mostowska, Monika K. Świderska, Wojciech Marcinkowski, Ireneusz Stolarek, Marek Figlerowicz, Paweł P. Jagodziński
    BMC Infectious Diseases.2021;[Epub]     CrossRef
  • Increased levels of circulating IL-10 in persons recovered from hepatitis C virus (HCV) infection compared with persons with active HCV infection
    Dorcas Ohui Owusu, Richard Phillips, Michael Owusu, Fred Stephen Sarfo, Margaret Frempong
    BMC Research Notes.2020;[Epub]     CrossRef
  • A Success Story
    Nina Leung, Seth E. Bernacki, Edward J. Bernacki
    Journal of Occupational & Environmental Medicine.2019; 61(8): e354.     CrossRef
  • Management of acute HCV infection in the era of direct-acting antiviral therapy
    Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore, Gail V. Matthews
    Nature Reviews Gastroenterology & Hepatology.2018; 15(7): 412.     CrossRef
  • Hepatitis C Virus Genotype Analyses in Chronic Hepatitis C Patients and Individuals With Spontaneous Virus Clearance Using a Newly Developed Serotyping Assay
    Ruifeng Yang, Xiqin Yang, Bingshui Xiu, Huiying Rao, Ran Fei, Wenli Guan, Yan Liu, Qian Wang, Xiaoyan Feng, Heqiu Zhang, Lai Wei
    Journal of Clinical Laboratory Analysis.2017;[Epub]     CrossRef
  • Clinical epidemiology of acute hepatitis C in South America
    Melisa Dirchwolf, Sebastián Marciano, Ezequiel Mauro, Andrés Eduardo Ruf, Lucrecia Rezzonico, Margarita Anders, Daniela Chiodi, Néstor Gill Petta, Silvia Borzi, Federico Tanno, Ezequiel Ridruejo, Fernando Barreyro, Carolina Shulman, Pablo Plaza, Rodolfo C
    Journal of Medical Virology.2017; 89(2): 276.     CrossRef
  • Enhancing the detection and management of acute hepatitis C virus infection
    Marianne Martinello, Gail V. Matthews
    International Journal of Drug Policy.2015; 26(10): 899.     CrossRef
  • 11,444 View
  • 63 Download
  • 12 Web of Science
  • Crossref
Case Report
A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads
Dong Hoo Joh, Jin Dong Kim, Young Nam Kim, Ha Hun Song, Hyun Kim, Kyung Ho Song, Sang Jin Lee, Jeong Rok Lee, Won Joong Jeon, Byung Hyo Cha
Korean J Hepatol 2010;16(4):405-409.
Published online December 31, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.4.405

Hepatocellular carcinoma (HCC) in the caudate lobe remains one of the most intricate locations where various treatments tend to pose problems with regard to the optimal approach. Surgical resection has been regarded as the most effective treatment; however, isolated resection of the caudate lobe is strenuous and associated with a high rate of early recurrence. Percutaneous ablation might be technically difficult or impossible to perform due to the deep location of tumors and adjacent large vessels. Treatment with drug-eluting beads (DEB) can potentially enhance the therapeutic efficacy for patients with unresectable HCC by drawing on the slower, more consistent drug delivery process. We described a case of a 62-year-old man with HCC in the caudate lobe who was successfully treated by DEB.

Citations

Citations to this article as recorded by  Crossref logo
  • Fogarty-assisted flow redirection during conventional transarterial chemoembolization for caudate lobe hepatocellular carcinoma
    Darrel Ceballos, Albert Tine, Rakesh Varma, Husameddin El Khudari
    American Journal of Interventional Radiology.2022; 6: 1.     CrossRef
  • 8,923 View
  • 53 Download
  • Crossref